GLP-1 and Sleep Apnea: Can Weight-Loss Medication Help?

Obstructive sleep apnea (OSA) and obesity are closely linked — excess weight around the neck and chest narrows the airway during sleep, causing the repeated breathing interruptions that define OSA. GLP-1 medications, by producing significant weight loss, can meaningfully reduce sleep apnea severity. And in 2024, a major clinical trial made headlines by quantifying exactly how much.

The obesity–OSA link

Obesity is the single largest modifiable risk factor for OSA. In Malaysia, where obesity rates continue to rise, OSA is increasingly common and often undiagnosed. Patients with OSA have higher risks of hypertension, cardiovascular disease, type 2 diabetes, and daytime impairment. The link to weight is mechanistic: fat deposits in the soft tissues of the upper airway, pharynx, and chest wall reduce functional airway size.

Tirzepatide and SURMOUNT-OSA: what the trial showed

The SURMOUNT-OSA trial (2024) was the first large-scale RCT to examine a GLP-1/GIP dual agonist (tirzepatide) specifically for OSA. The results were striking: patients on tirzepatide experienced a mean reduction of more than 40% in the Apnea-Hypopnea Index (AHI) — the primary measure of sleep apnea severity. Many patients moved from severe OSA to mild or no OSA by the end of the trial.

These findings were published in the New England Journal of Medicine and represent clinically meaningful improvements — not just statistical significance. Tirzepatide participants also showed improved sleep quality, reduced hypoxia burden, and better patient-reported outcomes.

Semaglutide evidence for OSA

Earlier observational and smaller trial data on semaglutide also showed improvements in AHI, though the effect sizes were generally smaller than those seen with tirzepatide. The SELECT cardiovascular outcomes trial (semaglutide) also reported reduced rates of sleep-disordered breathing outcomes as a secondary finding. The evidence points consistently in one direction: GLP-1 class medications improve OSA through weight loss.

GLP-1 complements — it does not replace — CPAP

CPAP (Continuous Positive Airway Pressure) remains the primary treatment for moderate-to-severe OSA. GLP-1 medication is not a CPAP replacement. Rather, it addresses the root metabolic cause while CPAP manages the immediate airway risk. Many patients who achieve significant weight loss on GLP-1 are eventually able to step down their CPAP pressure or, in some cases, discontinue it — but this requires formal reassessment by a respiratory specialist.

When OSA resolves completely

A significant proportion of patients with obesity-related OSA experience complete resolution of the condition with sufficient weight loss (typically 10–15% of body weight). When this occurs, it should be confirmed with a repeat sleep study before stopping CPAP. Never stop CPAP simply because you have lost weight and feel better — OSA can persist even as symptoms improve.

Seimbang's approach

At Seimbang, sleep apnea is one of the recognised comorbidities that qualifies patients with a BMI ≥27.5 for GLP-1 treatment. If you have diagnosed OSA (or strongly suspect it), your Seimbang doctor will factor this into your treatment plan and may recommend formal sleep assessment if you have not yet been diagnosed. Treatment plans are developed with your full metabolic and cardiovascular profile in view.

Frequently Asked Questions